BofA analyst Tazeen Ahmad raised the firm’s price target on Neurocrine Biosciences to $137 from $136 and keeps a Buy rating on the shares after Neurocrine announced U.S. approval of Ingrezza for the treatment of chorea associated with Huntington’s disease, or HD. The firm, which sees the approval in this new indication as in-line with expectations, calls this news a positive, but highlights that tardive dyskinesia, or TD, continues to be the bigger value driver.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NBIX:
- Neurocrine Stock (NASDAQ:NBIX): Investors and Analysts are Bullish
- Neurocrine announces FDA approval of Ingrezza
- Neurocrine price target raised to $132 from $130 at Canaccord
- Neurocrine price target raised to $135 from $127 at Cantor Fitzgerald
- Neurocrine price target raised to $125 from $120 at TD Cowen